Sun Pharma jumps on reporting 43% rise in Q1 consolidated net profit

Sun Pharma is currently trading at Rs. 941.10, up by 46.35 points or 5.18% from its previous closing of Rs. 894.75 on the BSE.

The scrip opened at Rs. 894.00 and has touched a high and low of Rs. 951.25 and Rs. 879.00 respectively. So far 442541 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 966.90 on 29-Apr-2022 and a 52 week low of Rs. 680.75 on 29-Jul-2021.

Pharma drugs cadila sun pharma 1280 770x433
Pharma drugs cadila sun pharma 1280 770×433

Last one week high and low of the scrip stood at Rs. 951.25 and Rs. 856.60 respectively. The current market cap of the company is Rs. 225753.43 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 34.61% and 10.91% respectively.

Sun Pharmaceutical Industries has reported net profit at Rs 1,011.80 crore for first quarter ended June 30, 2022 as compared to net loss of Rs 138.28 crore for the same quarter in the previous year. Total income of the company increased by 33.44% at Rs 4,981.87 crore for Q1FY23 as compared Rs 3,733.30 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 42.70% in its net profit after taxes, share of profit of associates and joint venture and non-controlling interests at Rs 2,060.88 crore for first quarter ended June 30, 2022 review as compared to Rs 1,444.17 crore for the same quarter in the previous year. Total income of the company increased by 9.04% at Rs 10,763.90 crore for Q1FY23 as compared Rs 9,871.26 crore for the corresponding quarter previous year.